251 related articles for article (PubMed ID: 16809766)
1. Wnt activation and alternative promoter repression of LEF1 in colon cancer.
Li TW; Ting JH; Yokoyama NN; Bernstein A; van de Wetering M; Waterman ML
Mol Cell Biol; 2006 Jul; 26(14):5284-99. PubMed ID: 16809766
[TBL] [Abstract][Full Text] [Related]
2. A unique DNA binding domain converts T-cell factors into strong Wnt effectors.
Atcha FA; Syed A; Wu B; Hoverter NP; Yokoyama NN; Ting JH; Munguia JE; Mangalam HJ; Marsh JL; Waterman ML
Mol Cell Biol; 2007 Dec; 27(23):8352-63. PubMed ID: 17893322
[TBL] [Abstract][Full Text] [Related]
3. Beta-catenin-sensitive isoforms of lymphoid enhancer factor-1 are selectively expressed in colon cancer.
Hovanes K; Li TW; Munguia JE; Truong T; Milovanovic T; Lawrence Marsh J; Holcombe RF; Waterman ML
Nat Genet; 2001 May; 28(1):53-7. PubMed ID: 11326276
[TBL] [Abstract][Full Text] [Related]
4. Mastermind-like 1 Is a specific coactivator of beta-catenin transcription activation and is essential for colon carcinoma cell survival.
Alves-Guerra MC; Ronchini C; Capobianco AJ
Cancer Res; 2007 Sep; 67(18):8690-8. PubMed ID: 17875709
[TBL] [Abstract][Full Text] [Related]
5. Targeting the WNT/beta-catenin/TCF/LEF1 axis in solid and haematological cancers: Multiplicity of therapeutic options.
Gehrke I; Gandhirajan RK; Kreuzer KA
Eur J Cancer; 2009 Nov; 45(16):2759-67. PubMed ID: 19729298
[TBL] [Abstract][Full Text] [Related]
6. A new beta-catenin-dependent activation domain in T cell factor.
Atcha FA; Munguia JE; Li TW; Hovanes K; Waterman ML
J Biol Chem; 2003 May; 278(18):16169-75. PubMed ID: 12582159
[TBL] [Abstract][Full Text] [Related]
7. A role for YY1 in repression of dominant negative LEF-1 expression in colon cancer.
Yokoyama NN; Pate KT; Sprowl S; Waterman ML
Nucleic Acids Res; 2010 Oct; 38(19):6375-88. PubMed ID: 20525792
[TBL] [Abstract][Full Text] [Related]
8. A Tcf/Lef element within the enhancer region of the human NANOG gene plays a role in promoter activation.
Kim CG; Chung IY; Lim Y; Lee YH; Shin SY
Biochem Biophys Res Commun; 2011 Jul; 410(3):637-42. PubMed ID: 21689639
[TBL] [Abstract][Full Text] [Related]
9. Wnt-promoted Isl1 expression through a novel TCF/LEF1 binding site and H3K9 acetylation in early stages of cardiomyocyte differentiation of P19CL6 cells.
Lu H; Li Y; Wang Y; Liu Y; Wang W; Jia Z; Chen P; Ma K; Zhou C
Mol Cell Biochem; 2014 Jun; 391(1-2):183-92. PubMed ID: 24610003
[TBL] [Abstract][Full Text] [Related]
10. Down-regulation of monocyte chemotactic protein-3 by activated beta-catenin.
Fujita M; Furukawa Y; Nagasawa Y; Ogawa M; Nakamura Y
Cancer Res; 2000 Dec; 60(23):6683-7. PubMed ID: 11118053
[TBL] [Abstract][Full Text] [Related]
11. Lymphoid enhancer factor-1 mediates loading of Pax3 to a promoter harbouring lymphoid enhancer factor-1 binding sites resulting in enhancement of transcription.
Christova T; Mojtahedi G; Hamel PA
Int J Biochem Cell Biol; 2010 May; 42(5):630-40. PubMed ID: 20006729
[TBL] [Abstract][Full Text] [Related]
12. Selective targeting to the hyperactive beta-catenin/T-cell factor pathway in colon cancer cells.
Chen RH; McCormick F
Cancer Res; 2001 Jun; 61(11):4445-9. PubMed ID: 11389074
[TBL] [Abstract][Full Text] [Related]
13. A beta-catenin/TCF-coordinated chromatin loop at MYC integrates 5' and 3' Wnt responsive enhancers.
Yochum GS; Sherrick CM; Macpartlin M; Goodman RH
Proc Natl Acad Sci U S A; 2010 Jan; 107(1):145-50. PubMed ID: 19966299
[TBL] [Abstract][Full Text] [Related]
14. Differentiation-inducing factor-1 alters canonical Wnt signaling and suppresses alkaline phosphatase expression in osteoblast-like cell lines.
Matsuzaki E; Takahashi-Yanaga F; Miwa Y; Hirata M; Watanabe Y; Sato N; Morimoto S; Hirofuji T; Maeda K; Sasaguri T
J Bone Miner Res; 2006 Aug; 21(8):1307-16. PubMed ID: 16869729
[TBL] [Abstract][Full Text] [Related]
15. Hepatocyte nuclear factor 1β suppresses canonical Wnt signaling through transcriptional repression of lymphoid enhancer-binding factor 1.
Chan SC; Hajarnis SS; Vrba SM; Patel V; Igarashi P
J Biol Chem; 2020 Dec; 295(51):17560-17572. PubMed ID: 33453998
[TBL] [Abstract][Full Text] [Related]
16. Fusion of the BCL9 HD2 domain to E1A increases the cytopathic effect of an oncolytic adenovirus that targets colon cancer cells.
Fuerer C; Homicsko K; Lukashev AN; Pittet AL; Iggo RD
BMC Cancer; 2006 Oct; 6():236. PubMed ID: 17020613
[TBL] [Abstract][Full Text] [Related]
17. Identification of SP5 as a downstream gene of the beta-catenin/Tcf pathway and its enhanced expression in human colon cancer.
Takahashi M; Nakamura Y; Obama K; Furukawa Y
Int J Oncol; 2005 Dec; 27(6):1483-7. PubMed ID: 16273202
[TBL] [Abstract][Full Text] [Related]
18. Human FasL gene is a target of β-catenin/T-cell factor pathway and complex FasL haplotypes alter promoter functions.
Wu J; Richards MH; Huang J; Al-Harthi L; Xu X; Lin R; Xie F; Gibson AW; Edberg JC; Kimberly RP
PLoS One; 2011; 6(10):e26143. PubMed ID: 22022540
[TBL] [Abstract][Full Text] [Related]
19. TIP49 regulates beta-catenin-mediated neoplastic transformation and T-cell factor target gene induction via effects on chromatin remodeling.
Feng Y; Lee N; Fearon ER
Cancer Res; 2003 Dec; 63(24):8726-34. PubMed ID: 14695187
[TBL] [Abstract][Full Text] [Related]
20. Mapping of the Wnt/β-catenin/TCF response elements in the human versican promoter.
Rahmani M; Carthy JM; McManus BM
Methods Mol Biol; 2012; 836():35-52. PubMed ID: 22252626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
